WO2015032841A3 - Methods and pharmaceutical compositions for prevention or treatment of th17 mediated disease - Google Patents
Methods and pharmaceutical compositions for prevention or treatment of th17 mediated disease Download PDFInfo
- Publication number
- WO2015032841A3 WO2015032841A3 PCT/EP2014/068782 EP2014068782W WO2015032841A3 WO 2015032841 A3 WO2015032841 A3 WO 2015032841A3 EP 2014068782 W EP2014068782 W EP 2014068782W WO 2015032841 A3 WO2015032841 A3 WO 2015032841A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prevention
- treatment
- methods
- mediated disease
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Rehabilitation Therapy (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to methods and compositions for the prevention or treatment of Th 17 mediated disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13306216.6 | 2013-09-05 | ||
EP13306216 | 2013-09-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015032841A2 WO2015032841A2 (en) | 2015-03-12 |
WO2015032841A3 true WO2015032841A3 (en) | 2015-05-28 |
Family
ID=49150890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2014/068782 WO2015032841A2 (en) | 2013-09-05 | 2014-09-04 | Methods and pharmaceutical compositions for prevention or treatment of th17 mediated disease |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2015032841A2 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001066098A2 (en) * | 2000-03-09 | 2001-09-13 | Aventis Pharma Deutschland Gmbh | Therapeutic uses of ppar mediators |
WO2005116057A1 (en) * | 2004-05-27 | 2005-12-08 | Baker Medical Research Institute | Monoclonal antibody against abca1 |
EP1704857A1 (en) * | 2004-01-15 | 2006-09-27 | ASKA Pharmaceutical Co., Ltd. | Abca1 stabilizer |
WO2009055538A1 (en) * | 2007-10-23 | 2009-04-30 | The Cleveland Clinic Foundation | Oxidant resistant apolipoprotein a-1 and mimetic peptides |
US20090203689A1 (en) * | 2008-02-07 | 2009-08-13 | Arvinder Dhalla | Abca-1 elevating compounds and methods |
US20130065911A1 (en) * | 2011-09-12 | 2013-03-14 | Uwe Grether | N-(5-cycloalkyl- or 5-heterocyclyl-)-pyridin-3-yl carboxamides |
-
2014
- 2014-09-04 WO PCT/EP2014/068782 patent/WO2015032841A2/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001066098A2 (en) * | 2000-03-09 | 2001-09-13 | Aventis Pharma Deutschland Gmbh | Therapeutic uses of ppar mediators |
EP1704857A1 (en) * | 2004-01-15 | 2006-09-27 | ASKA Pharmaceutical Co., Ltd. | Abca1 stabilizer |
WO2005116057A1 (en) * | 2004-05-27 | 2005-12-08 | Baker Medical Research Institute | Monoclonal antibody against abca1 |
WO2009055538A1 (en) * | 2007-10-23 | 2009-04-30 | The Cleveland Clinic Foundation | Oxidant resistant apolipoprotein a-1 and mimetic peptides |
US20090203689A1 (en) * | 2008-02-07 | 2009-08-13 | Arvinder Dhalla | Abca-1 elevating compounds and methods |
US20130065911A1 (en) * | 2011-09-12 | 2013-03-14 | Uwe Grether | N-(5-cycloalkyl- or 5-heterocyclyl-)-pyridin-3-yl carboxamides |
Non-Patent Citations (4)
Title |
---|
PURANIK ET AL: "Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo", ATHEROSCLEROSIS, ELSEVIER IRELAND LTD, IE, vol. 196, no. 1, 27 June 2007 (2007-06-27), pages 240 - 247, XP022416026, ISSN: 0021-9150, DOI: 10.1016/J.ATHEROSCLEROSIS.2007.05.008 * |
QUENTIN RAIMBOURG ET AL: "The Calpain/Calpastatin System Has Opposing Roles in Growth and Metastatic Dissemination of Melanoma", PLOS ONE, vol. 8, no. 4, 2 April 2013 (2013-04-02), pages e60469, XP055084604, DOI: 10.1371/journal.pone.0060469 * |
S. D. NANDEDKAR ET AL: "D-4F, an apoA-1 mimetic, decreases airway hyperresponsiveness, inflammation, and oxidative stress in a murine model of asthma", THE JOURNAL OF LIPID RESEARCH, vol. 52, no. 3, 3 December 2010 (2010-12-03), pages 499 - 508, XP055084597, ISSN: 0022-2275, DOI: 10.1194/jlr.M012724 * |
X. YAO ET AL: "5A, an Apolipoprotein A-I Mimetic Peptide, Attenuates the Induction of House Dust Mite-Induced Asthma", THE JOURNAL OF IMMUNOLOGY, vol. 186, no. 1, 29 November 2010 (2010-11-29), pages 576 - 583, XP055084522, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1001534 * |
Also Published As
Publication number | Publication date |
---|---|
WO2015032841A2 (en) | 2015-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017095944A8 (en) | Methods and compositions relating to chondrisomes from blood products | |
EP3448874A4 (en) | Compositions for the treatment of disease | |
EP3448875A4 (en) | Compositions for the treatment of disease | |
EP3448987A4 (en) | Compositions for the treatment of disease | |
IL276153B (en) | C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency . | |
WO2016011306A3 (en) | Terminal modifications of polynucleotides | |
EP3318564A3 (en) | Bicyclic heterocycles as fgfr inhibitors | |
WO2015085318A3 (en) | Targeted adaptive vaccines | |
WO2016011222A3 (en) | Circular polynucleotides | |
WO2014130856A3 (en) | Treatment of skeletal-related disorders | |
WO2014151456A3 (en) | Treatment of inflammatory diseases | |
EP4218736A3 (en) | Compositions comprising 15-hepe | |
EP3182989A4 (en) | Methods and compositions for the prevention and treatment of disease | |
EP3528852A4 (en) | Methods and compositions for the treatment of fabry disease | |
WO2015092810A3 (en) | Amorphous form of idelalisib | |
CA2929436C (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
EP2978449A4 (en) | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection | |
CN106687453A8 (en) | As the tetrahydroquinoline derivative of bromine domain inhibitor | |
EP3522873A4 (en) | Compositions and methods for the treatment of xerostomia | |
EP3288636A4 (en) | Compositions for the treatment of epistaxis | |
WO2015080980A3 (en) | Treatment of autoimmune and/or inflammatory disease using novel caveolin modulators | |
EP2964750A4 (en) | Methods and compositions for the treatment and/or prevention of type 1 diabetes | |
EP3341079A4 (en) | Methods and compositions relating to the diagnosis and treatment of cancer | |
WO2016109002A3 (en) | Methods and compositions for the treatment of radiation-related disorders | |
EP3261446A4 (en) | Methods and compositions for the treatment or prevention of parkinson's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14766927 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14766927 Country of ref document: EP Kind code of ref document: A2 |